The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples
There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Gaebel, Wolfgang [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
11 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Idiopathic Environmental Intolerance: A Treatment Model - Van den Bergh, Omer ELSEVIER, 2021, an international multidisciplinary journal, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:225 ; year:2020 ; pages:4-14 ; extent:11 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.schres.2019.10.049 |
|---|
| Katalog-ID: |
ELV052480100 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV052480100 | ||
| 003 | DE-627 | ||
| 005 | 20230626033338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.schres.2019.10.049 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001236.pica |
| 035 | |a (DE-627)ELV052480100 | ||
| 035 | |a (ELSEVIER)S0920-9964(19)30484-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 150 |q VZ |
| 100 | 1 | |a Gaebel, Wolfgang |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples |
| 264 | 1 | |c 2020transfer abstract | |
| 300 | |a 11 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. | ||
| 520 | |a There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. | ||
| 650 | 7 | |a Schizophrenia |2 Elsevier | |
| 650 | 7 | |a Pharmacotherapy |2 Elsevier | |
| 650 | 7 | |a Guideline |2 Elsevier | |
| 650 | 7 | |a Antipsychotic |2 Elsevier | |
| 650 | 7 | |a Long-term |2 Elsevier | |
| 650 | 7 | |a Maintenance |2 Elsevier | |
| 700 | 1 | |a Stricker, Johannes |4 oth | |
| 700 | 1 | |a Riesbeck, Mathias |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Van den Bergh, Omer ELSEVIER |t Idiopathic Environmental Intolerance: A Treatment Model |d 2021 |d an international multidisciplinary journal |g Amsterdam [u.a.] |w (DE-627)ELV005829860 |
| 773 | 1 | 8 | |g volume:225 |g year:2020 |g pages:4-14 |g extent:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.schres.2019.10.049 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 951 | |a AR | ||
| 952 | |d 225 |j 2020 |h 4-14 |g 11 | ||
| author_variant |
w g wg |
|---|---|
| matchkey_str |
gaebelwolfgangstrickerjohannesriesbeckma:2020----:hlntratpyhtcramnoshzprnaslcieeiwflnclud |
| hierarchy_sort_str |
2020transfer abstract |
| publishDate |
2020 |
| allfields |
10.1016/j.schres.2019.10.049 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001236.pica (DE-627)ELV052480100 (ELSEVIER)S0920-9964(19)30484-0 DE-627 ger DE-627 rakwb eng 150 VZ Gaebel, Wolfgang verfasserin aut The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples 2020transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. Schizophrenia Elsevier Pharmacotherapy Elsevier Guideline Elsevier Antipsychotic Elsevier Long-term Elsevier Maintenance Elsevier Stricker, Johannes oth Riesbeck, Mathias oth Enthalten in Elsevier Science Van den Bergh, Omer ELSEVIER Idiopathic Environmental Intolerance: A Treatment Model 2021 an international multidisciplinary journal Amsterdam [u.a.] (DE-627)ELV005829860 volume:225 year:2020 pages:4-14 extent:11 https://doi.org/10.1016/j.schres.2019.10.049 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 225 2020 4-14 11 |
| spelling |
10.1016/j.schres.2019.10.049 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001236.pica (DE-627)ELV052480100 (ELSEVIER)S0920-9964(19)30484-0 DE-627 ger DE-627 rakwb eng 150 VZ Gaebel, Wolfgang verfasserin aut The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples 2020transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. Schizophrenia Elsevier Pharmacotherapy Elsevier Guideline Elsevier Antipsychotic Elsevier Long-term Elsevier Maintenance Elsevier Stricker, Johannes oth Riesbeck, Mathias oth Enthalten in Elsevier Science Van den Bergh, Omer ELSEVIER Idiopathic Environmental Intolerance: A Treatment Model 2021 an international multidisciplinary journal Amsterdam [u.a.] (DE-627)ELV005829860 volume:225 year:2020 pages:4-14 extent:11 https://doi.org/10.1016/j.schres.2019.10.049 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 225 2020 4-14 11 |
| allfields_unstemmed |
10.1016/j.schres.2019.10.049 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001236.pica (DE-627)ELV052480100 (ELSEVIER)S0920-9964(19)30484-0 DE-627 ger DE-627 rakwb eng 150 VZ Gaebel, Wolfgang verfasserin aut The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples 2020transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. Schizophrenia Elsevier Pharmacotherapy Elsevier Guideline Elsevier Antipsychotic Elsevier Long-term Elsevier Maintenance Elsevier Stricker, Johannes oth Riesbeck, Mathias oth Enthalten in Elsevier Science Van den Bergh, Omer ELSEVIER Idiopathic Environmental Intolerance: A Treatment Model 2021 an international multidisciplinary journal Amsterdam [u.a.] (DE-627)ELV005829860 volume:225 year:2020 pages:4-14 extent:11 https://doi.org/10.1016/j.schres.2019.10.049 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 225 2020 4-14 11 |
| allfieldsGer |
10.1016/j.schres.2019.10.049 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001236.pica (DE-627)ELV052480100 (ELSEVIER)S0920-9964(19)30484-0 DE-627 ger DE-627 rakwb eng 150 VZ Gaebel, Wolfgang verfasserin aut The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples 2020transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. Schizophrenia Elsevier Pharmacotherapy Elsevier Guideline Elsevier Antipsychotic Elsevier Long-term Elsevier Maintenance Elsevier Stricker, Johannes oth Riesbeck, Mathias oth Enthalten in Elsevier Science Van den Bergh, Omer ELSEVIER Idiopathic Environmental Intolerance: A Treatment Model 2021 an international multidisciplinary journal Amsterdam [u.a.] (DE-627)ELV005829860 volume:225 year:2020 pages:4-14 extent:11 https://doi.org/10.1016/j.schres.2019.10.049 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 225 2020 4-14 11 |
| allfieldsSound |
10.1016/j.schres.2019.10.049 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001236.pica (DE-627)ELV052480100 (ELSEVIER)S0920-9964(19)30484-0 DE-627 ger DE-627 rakwb eng 150 VZ Gaebel, Wolfgang verfasserin aut The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples 2020transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. Schizophrenia Elsevier Pharmacotherapy Elsevier Guideline Elsevier Antipsychotic Elsevier Long-term Elsevier Maintenance Elsevier Stricker, Johannes oth Riesbeck, Mathias oth Enthalten in Elsevier Science Van den Bergh, Omer ELSEVIER Idiopathic Environmental Intolerance: A Treatment Model 2021 an international multidisciplinary journal Amsterdam [u.a.] (DE-627)ELV005829860 volume:225 year:2020 pages:4-14 extent:11 https://doi.org/10.1016/j.schres.2019.10.049 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 225 2020 4-14 11 |
| language |
English |
| source |
Enthalten in Idiopathic Environmental Intolerance: A Treatment Model Amsterdam [u.a.] volume:225 year:2020 pages:4-14 extent:11 |
| sourceStr |
Enthalten in Idiopathic Environmental Intolerance: A Treatment Model Amsterdam [u.a.] volume:225 year:2020 pages:4-14 extent:11 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Schizophrenia Pharmacotherapy Guideline Antipsychotic Long-term Maintenance |
| dewey-raw |
150 |
| isfreeaccess_bool |
false |
| container_title |
Idiopathic Environmental Intolerance: A Treatment Model |
| authorswithroles_txt_mv |
Gaebel, Wolfgang @@aut@@ Stricker, Johannes @@oth@@ Riesbeck, Mathias @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV005829860 |
| dewey-sort |
3150 |
| id |
ELV052480100 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV052480100</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626033338.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.schres.2019.10.049</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001236.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV052480100</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0920-9964(19)30484-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gaebel, Wolfgang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Schizophrenia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Guideline</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antipsychotic</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Long-term</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Maintenance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stricker, Johannes</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Riesbeck, Mathias</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Van den Bergh, Omer ELSEVIER</subfield><subfield code="t">Idiopathic Environmental Intolerance: A Treatment Model</subfield><subfield code="d">2021</subfield><subfield code="d">an international multidisciplinary journal</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV005829860</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:225</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:4-14</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.schres.2019.10.049</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">225</subfield><subfield code="j">2020</subfield><subfield code="h">4-14</subfield><subfield code="g">11</subfield></datafield></record></collection>
|
| author |
Gaebel, Wolfgang |
| spellingShingle |
Gaebel, Wolfgang ddc 150 Elsevier Schizophrenia Elsevier Pharmacotherapy Elsevier Guideline Elsevier Antipsychotic Elsevier Long-term Elsevier Maintenance The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples |
| authorStr |
Gaebel, Wolfgang |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV005829860 |
| format |
electronic Article |
| dewey-ones |
150 - Psychology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
150 VZ The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples Schizophrenia Elsevier Pharmacotherapy Elsevier Guideline Elsevier Antipsychotic Elsevier Long-term Elsevier Maintenance Elsevier |
| topic |
ddc 150 Elsevier Schizophrenia Elsevier Pharmacotherapy Elsevier Guideline Elsevier Antipsychotic Elsevier Long-term Elsevier Maintenance |
| topic_unstemmed |
ddc 150 Elsevier Schizophrenia Elsevier Pharmacotherapy Elsevier Guideline Elsevier Antipsychotic Elsevier Long-term Elsevier Maintenance |
| topic_browse |
ddc 150 Elsevier Schizophrenia Elsevier Pharmacotherapy Elsevier Guideline Elsevier Antipsychotic Elsevier Long-term Elsevier Maintenance |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j s js m r mr |
| hierarchy_parent_title |
Idiopathic Environmental Intolerance: A Treatment Model |
| hierarchy_parent_id |
ELV005829860 |
| dewey-tens |
150 - Psychology |
| hierarchy_top_title |
Idiopathic Environmental Intolerance: A Treatment Model |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV005829860 |
| title |
The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples |
| ctrlnum |
(DE-627)ELV052480100 (ELSEVIER)S0920-9964(19)30484-0 |
| title_full |
The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples |
| author_sort |
Gaebel, Wolfgang |
| journal |
Idiopathic Environmental Intolerance: A Treatment Model |
| journalStr |
Idiopathic Environmental Intolerance: A Treatment Model |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
100 - Philosophy & psychology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
4 |
| author_browse |
Gaebel, Wolfgang |
| container_volume |
225 |
| physical |
11 |
| class |
150 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Gaebel, Wolfgang |
| doi_str_mv |
10.1016/j.schres.2019.10.049 |
| dewey-full |
150 |
| title_sort |
long-term antipsychotic treatment of schizophrenia: a selective review of clinical guidelines and clinical case examples |
| title_auth |
The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples |
| abstract |
There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. |
| abstractGer |
There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. |
| abstract_unstemmed |
There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples |
| url |
https://doi.org/10.1016/j.schres.2019.10.049 |
| remote_bool |
true |
| author2 |
Stricker, Johannes Riesbeck, Mathias |
| author2Str |
Stricker, Johannes Riesbeck, Mathias |
| ppnlink |
ELV005829860 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.schres.2019.10.049 |
| up_date |
2024-07-06T23:08:52.156Z |
| _version_ |
1803872981124907008 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV052480100</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626033338.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.schres.2019.10.049</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001236.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV052480100</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0920-9964(19)30484-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gaebel, Wolfgang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Schizophrenia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Guideline</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antipsychotic</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Long-term</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Maintenance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stricker, Johannes</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Riesbeck, Mathias</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Van den Bergh, Omer ELSEVIER</subfield><subfield code="t">Idiopathic Environmental Intolerance: A Treatment Model</subfield><subfield code="d">2021</subfield><subfield code="d">an international multidisciplinary journal</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV005829860</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:225</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:4-14</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.schres.2019.10.049</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">225</subfield><subfield code="j">2020</subfield><subfield code="h">4-14</subfield><subfield code="g">11</subfield></datafield></record></collection>
|
| score |
7.399747 |